On October 21st, Sanofi announced it has entered into exclusive negotiations with CD&R to sell a controlling stake in Opella. This announcement is a major and exciting milestone on our journey to becoming a leading fast-moving consumer healthcare player globally.

3 days ago · The decision to divest Opella is part of Sanofi’s ongoing strategy to become a pureplay biopharma company. Opella employs more than 11,000 people worldwide and is known for making Doliprane, one of France’s most-sold paracetamol-based painkillers. The medicine is so popular that most paracetamol products are referred to as Doliprane ...

4 days ago · Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&R. Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder.

4 days ago · Sanofi and CD&R sign Opella share purchase agreement. Paris, February 19, 2025.Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed ...

Oct 30, 2024 · Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and...

Oct 21, 2024 · Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a …

Oct 21, 2005 · Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a …

Oct 11, 2006 · Sanofi in discussions to sell a controlling stake in Opella. Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.

Oct 21, 2024 · French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice...

Oct 21, 2024 · Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations...